Category: Portfolio Leadership

Serta Simmons donates 10,000+ mattresses to NYC Hospitals

Serta Simmons (SSB), North America’s largest bedding manufacturer, has donated 10,000 mattresses to help meet increased demand for bed space in the hospitals and temporary medical facilities fighting Covid-19 in New York.

Mattress capacity per day
While the healthcare system’s shortages of masks and ventilators have been widely publicized, the need for extra bedding has been largely overlooked. Through Relief Bed International, these beds were delivered starting April 3, 2020.
On top of the mattress donation for New York, SSB has pledged to mobilize its factories and distribution network across the country to provide as many as 20,000 beds per day at the lowest possible cost.
In an effort to encourage others to follow its lead, the company has also launched “Stay Home, Send Beds,” a program that facilitates nationwide bed donations during the pandemic. Donors can purchase up to 10,000 beds for their US city of choice and Serta will donate an additional mattress for every 25 purchased. To learn more or contribute to the cause, please visit:

BioDuro’s quest for a nanobody therapy to combat coronavirus

BioDuro is harnessing its world-leading biopharmaceutical expertise to fight the coronavirus pandemic. A specialized team is leveraging the firm’s acclaimed biologics discovery program to find an effective nanobody therapy for Covid-19 patients.

Human synthetic antibodies screened
The program is sponsored by the Global Health Drug Discovery Institute (GHDDI), which is jointly founded by the Bill and Melinda Gates Foundation, Tsinghua University and Beijing Municipal Government.
BioDuro’s initiative uses advanced synthetic antibody technology to find a way of blocking the virus’s entry and fusion into human cells. This process involves screening more than 10 billion human synthetic antibodies, all generated using Artificial Intelligence (AI) computing and high-speed DNA mutagenesis technology.
The aim of the program is to discover which antibody disrupts the Covid-19 virus most optimally. This will enable scientists to produce a nanobody: an antibody that contains only the single, tiny unit needed for recognition and disruption of Covid-19 targets.
Thanks to their small size, nanobodies are extremely effective at penetrating human tissue – such as when delivered in a spray to the lungs – ensuring a high dose is received.
The dedicated Covid-19 team includes scientists from a wide range of specialisms, including AI, phage display, assay development, protein purification, cell biology and biochemistry.
In a separate initiative, BioDuro has also partnered with the UC San Diego Health System and Scripps Health – a nonprofit health system based in the city – to augment their hospitals’ supply of personal protective equipment (PPE), and produce additional stocks of hand sanitizer.
Headquartered in San Diego, CA, USA, BioDuro is a leading global life-sciences contract research and development organization. The company has cutting-edge facilities in Beijing and Shanghai, China, and a fourth site is under construction in Wuxi.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google